Trading / Browse Companies / Mammoth Biosciences Stock

Mammoth Biosciences Stock

mammoth.bioBioTechFounded: 2017Funding to Date: $257.38MM

Mammoth Biosciences is a biotechnology company that, through the discovery and development of novel CRISPR systems, the is enabling the full potential of its platform to improve lives by reading and writing the code of life.

Buy or sell Mammoth Biosciences stock
Register for Details

For more details on financing and valuation for Mammoth Biosciences, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Mammoth Biosciences.

Register Today

Mammoth Biosciences investors also invested in these private companies

Decheng Capital
Foresite Capital
Mayfield Fund
NFX
Redmile Group

Team

Management Team

Trevor Martin Ph.D
Co-Founder & Chief Executive Officer
Ted Tisch
Chief Operating Officer
Janice Chen Ph.D
Co-Founder & Chief Technology Officer
Lucas Harrington
Co-Founder & Chief Scientific Officer
Peter Nell Ph.D
Chief Business Officer & Head of Therapeutics
Jennifer Doudna Ph.D
Co-Founder & Chairman of Scientific Advisory Board

Board Members

Jennifer Doudna Ph.D
Mammoth Biosciences
Ursheet Parikh
Mayfield Fund

Other companies like Mammoth Biosciences in the BioTech sector

Biosplice Therapeutics
Sector
BioTech
 
 
Grail
Sector
BioTech
Last Round Est. Valuation
$4.26B
Eikon Therapeutics
Sector
BioTech
Last Round Est. Valuation
$3.1B
Cytonics
Sector
BioTech
 
 
Resilience
Sector
BioTech
Last Round Est. Valuation
$5.81B
Synthego
Sector
BioTech
Last Round Est. Valuation
$1.3B
Element Biosciences
Sector
BioTech
Last Round Est. Valuation
$1.61B
Tessera
Sector
BioTech
Last Round Est. Valuation
$1.77B
Caris Life Sciences
Sector
BioTech
 
 

News

Crunchbase 09/09/2021
CRISPR biotech company Mammoth Biosciences gains unicorn status
San Francisco-based Mammoth Biosciences has closed on a $150 million Series D led by Redmile Group, which now values the CRISPR biotech company at $1 billion, making it a new addition to the Crunchbase Unicorn Board.
Techcrunch 07/31/2020
Mammoth Biosciences’s CRISPR-based COVID-19 test receives NIH funding through RADx program – TechCrunch
CRISPR tech startup Mammoth Biosciences is among the companies that revealed backing from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) program on Friday. Mammoth received a contract to scale up its CRISPR-based SARS-CoV-2 diagnostic test in order to help address …
Techcrunch 05/20/2020
Mammoth Biosciences partners with GSK to develop handheld CRISPR-based COVID-19 test – TechCrunch
California-based Mammoth Biosciences has signed a powerful partner for its development of a CRISPR-based test for COVID-19, which would aim to delivery accurate, fast results using a handheld, disposable testing platform. Mammoth Biosciences will be using its DETECTR platform to develop the test, w…

Trending Companies

Frequently Asked Questions